Brian Pereira is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. Prior to joining Visterra, Dr. Pereira served as the President and CEO of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG.) At AMAG, Dr. Pereira raised four financing rounds at increasing valuations, and built the clinical development, manufacturing, supply-chain, and commercial infrastructure for the company’s iron therapy product for anemia. Earlier, he served as the President and CEO of a Tufts Medical Center Physician Organization, and his prior roles at Tufts Medical Center included interim COO, Vice-Chairman for Strategic Development of the Department of Medicine, and staff physician. Dr. Pereira serves on the Board of Directors of Biodel, Inc. (NASDAQ: BIOD) and NephroPlus Ltd. Previously, he was the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. He is an Adjunct Professor of Medicine at Tufts University School of Medicine and has contributed over 200 published scientific articles. He received his medical degree (MBBS) from St. John’s Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute, and MBA from Kellogg Graduate School of Management at Northwestern University.
Donna Ambrosino joined Visterra in 2012 as CMO. She comes to Visterra with over 25 years of experience in Infectious Diseases, vaccines and monoclonal antibody development. During the past 13 years she served as Executive Director/CEO of MassBiologics, a non-profit FDA licensed manufacturer of vaccines and biologics. While at MassBiologics, she discovered and led the development of monoclonal antibodies for treatment or prevention of SARS, Rabies, C.Difficile disease, and Hepatitis C. Prior to MassBiologics, she was an Associate Professor at Dana Farber Cancer Center and Children's Hospital, Harvard Medical School for 19 years. She is internationally recognized expert in Infectious Diseases, antibody therapeutics, and clinical trial design. Dr. Ambrosino received her AB in Biology from Harvard University and her MD from Dartmouth Medical School.
David Arkowitz has more than 20 years of finance and operations leadership experience in the healthcare, life sciences and biotechnology industries. Prior to joining Visterra, Mr. Arkowitz was at Mascoma Corporation, a bioconversion company, where he served as Chief Financial Officer and General Manager, Mascoma Grain Tech. Previously, he was Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a commercial stage public biopharmaceutical company, where he had a broad range of operational and general management responsibilities. Prior to his tenure at AMAG, he served as Chief Financial Officer of Idenix Pharmaceuticals where he managed the company’s initial public offering. Earlier in his career, he spent more than thirteen years at Merck & Co. including as Vice President and Controller of the U.S. sales and marketing division and as Controller of the global research and development division. Mr. Arkowitz served on the board of directors of Aegerion Pharmaceuticals and ImpactRx. He has a B.A. in Mathematics from Brandeis University and an M.B.A. from Columbia University.
Mark Boshar has over 25 years of experience in the biotechnology industry. He joined Visterra in 2008 and is responsible for business development and legal affairs. Prior to Visterra, Mr. Boshar was the Vice President of Legal Affairs for Dynogen Pharmaceuticals, a clinical-stage company focused on gastrointestinal disorders. In 1995, Mr. Boshar founded the legal department at Millennium Pharmaceuticals, and served as its Associate General Counsel/Chief Patent Counsel. During his tenure at Millennium, Mr. Boshar was responsible for the design and implementation of the company's patent strategies, technology licensing, and the legal diligence for corporate partnering transactions totaling more than $1 billion in funding. Mr. Boshar also served as Vice President of Legal Affairs for Vitivity, a Millennium subsidiary. Prior to Millennium, Mr. Boshar was the Chief Patent Counsel for Repligen Corporation. Mr. Boshar was formerly an attorney with the law firm of Hale and Dorr (now WilmerHale). He received his JD from Northeastern University School of Law and his BS in Biology from Tufts University. Prior to receiving his law degree, he was a research scientist with both Genetics Institute and the Worcester Foundation for Experimental Biology.
Greg Miller has more than a decade of pharmaceutical business development experience and has established partnerships in the biopharmaceutical industry generating more than $100 million in upfront payments and over $1.5 billion in potential future milestones. Prior to joining Visterra, Mr. Miller served as Vice President of Business and Corporate Development at Concert Pharmaceuticals where he secured numerous collaborations related to the company's drug development platform, including transactions with Avanir Pharmaceuticals, Jazz Pharmaceuticals, and Celgene Corporation. Previously, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals where he led the efforts in establishing a multi-regional partnership with Takeda Pharmaceuticals. Mr. Miller began his pharmaceutical career at Genzyme Corporation in 2002, where he held various roles in business development, licensing, marketing, and reimbursement. He holds a B.A. in Psychology from Brandeis University, and both an M.B.A. and an M.P.H. from Boston University.
Zach Shriver is Visterra's Vice President of Research. Dr. Shriver has over 10 years of experience in the biotechnology industry and joined Visterra in 2009. He was one of the founding scientists at Momenta Pharmaceuticals and served as its Senior Director of Research Analytics. While at Momenta, Dr. Shriver was responsible for leading a variety of activities, including integrating information from state-of-the-art analytical techniques into the design, control, and enablement of increased process understanding for a number of complex mixture (polysaccharide and polypeptide) products, in support of multiple NDAs. Dr. Shriver received his PhD in applied biotechnology from MIT, in the area of sequencing complex polysaccharides through the integration of analytical and bioinformatics-based techniques. Dr. Shriver has authored over 50 publications, including original research on both the structure and biology of complex polysaccharides.